Kintor Pharmaceutical Limited
Research Kintor Pharmaceutical Limited (9939.HK) on Bullrun: market cap HKD 735.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9939.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 735.79M
- Financial periodFY2025
- RevenueCNY 32.68M
- Revenue growth553.6%
- Net income-CNY 200.11M
- Free cash flow-CNY 170.48M
- Gross margin24.6%
Valuation Snapshot
latest market cap is HKD 735.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 32.68M | -CNY 200.11M | -CNY 170.48M | 24.6% | n/a | CNY 32.74M | CNY 86.60M | CNY 182.60M |
| FY2024 | CNY 5.00M | -CNY 155.29M | -CNY 200.76M | -94.6% | -0.36 | CNY 147.42M | CNY 133.01M | CNY 294.08M |
| FY2023 | CNY 0 | -CNY 1.06B | -CNY 390.30M | n/a | -2.47 | CNY 445.50M | CNY 253.92M | CNY 458.11M |
| FY2022 | CNY 0 | -CNY 954.37M | -CNY 988.91M | n/a | -2.53 | CNY 865.08M | CNY 286.39M | CNY 1.50B |
| FY2021 | n/a | n/a | n/a | n/a | -2.36 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 735.79M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kintor Pharmaceutical Limited's market cap?
Kintor Pharmaceutical Limited's market capitalization is HKD 735.79M.
What does Kintor Pharmaceutical Limited do?
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial.